Floatz logo

Abt-263

Lymphoid Malignancies

AbbViePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Lymphoid Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2B
Fludarabine
M.D. Anderson Cancer Center
Phase 2B
CARMUSTINE
M.D. Anderson Cancer Center
Phase 2B

View all 33 →

Same molecule, other indications

Abt-263 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
62 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →